drugset
drugset / Trial / NCT05036798

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

NCT05036798 ↗

Phase 2 Unknown 30 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open, Phase II clinical study of Tislelizumab combined with lenvatinib and Gemox regimen for transformational treatment of potentially resectable locally advanced malignant tumors of biliary system.

Timeline

Start
2021-09-17
Primary completion
2022-07-02
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 —
Subject Lenvatinib Small molecule 4 mg Oral
Subject Oxaliplatin Small molecule 100 unknown —
Subject Tislelizumab Monoclonal antibody 200 mg —

Indications

biliary tract cancer